{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Regulatory-Submissions-IND-CTA-CTN”
},
“headline”: “SOP for Regulatory Submissions in Clinical Research (IND/CTA/CTN)”,
“description”: “A detailed SOP aligned with ICH GCP, WHO, and GMP guidelines for managing regulatory submissions such as IND, CTA, and CTN in global clinical trials.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Regulatory Submissions in Clinical Trials (IND/CTA/CTN)

Purpose

The purpose of this SOP is to outline the standardized process for preparing, reviewing, submitting, and tracking clinical trial regulatory submissions including Investigational New Drug (IND) applications, Clinical Trial Applications (CTA), and Clinical Trial Notifications (CTN). This ensures compliance with ICH-GCP, GMP, WHO, and local regulatory requirements (e.g., US FDA, EMA, CDSCO, MHRA, TGA).

Scope

This SOP applies to all regulatory affairs staff, clinical research teams, investigators, and sponsors involved in the preparation and submission of clinical trial applications across global regions. It covers dossier compilation, submission formats (e.g., eCTD), timelines, communications with authorities, and documentation retention.

Responsibilities

• Regulatory Affairs Manager: Oversees the preparation and accuracy of submissions.
• Clinical Research Associate: Provides protocol-related information for submissions.
• Principal Investigator: Ensures scientific and ethical accuracy of data included in submissions.
• Quality Assurance Officer: Reviews submission documents for compliance with SOP and regulations.
• Head of Clinical Research: Approves submissions prior to dispatch.

Accountability

The Regulatory Affairs Head is accountable for ensuring all submissions comply with applicable regulations and timelines. Non-compliance may lead to regulatory delays, rejection, or penalties.

Procedure

1. Pre-Submission Preparation
Identify the type of submission required (IND, CTA, or CTN).
Collect necessary documents including Investigator’s Brochure (IB), Clinical Trial Protocol, Chemistry Manufacturing and Controls (CMC) data, and preclinical data.
Assign responsibilities to team members for document drafting, review, and compilation.

2. Compilation of Submission Dossier
Ensure all documents are formatted according to agency requirements (e.g., FDA eCTD, EMA Module 1–5).
Cross-verify data with source records and clinical trial protocol.
Include quality certificates such as Certificate of Analysis (CoA) for investigational products.
Prepare country-specific annexures as per local guidelines.

3. Review and Quality Check
QA to review the submission package against regulatory checklists.
All discrepancies must be corrected before submission.
Maintain version control for each submission document.

4. Submission to Regulatory Authority
Submit documents electronically via eCTD gateway or in paper form if required by specific agency.
Obtain electronic acknowledgment from the regulatory authority.
Ensure timelines are tracked to meet statutory deadlines.

5. Post-Submission Follow-up
Track authority queries and respond within stipulated timeframes.
Document all communications with regulatory authorities.
Maintain submission tracker for all IND/CTA/CTN filings.

6. Documentation and Archiving
Archive submission packages in Trial Master File (TMF) or eTMF.
Retain records for a minimum of 5 years post trial completion or as per local regulations.

Abbreviations

• SOP: Standard Operating Procedure
• IND: Investigational New Drug
• CTA: Clinical Trial Application
• CTN: Clinical Trial Notification
• IB: Investigator’s Brochure
• CMC: Chemistry Manufacturing and Controls
• CoA: Certificate of Analysis
• QA: Quality Assurance
• eCTD: Electronic Common Technical Document
• TMF: Trial Master File

Documents

1. Submission Checklist (Annexure-1)
2. Submission Tracker (Annexure-2)
3. Regulatory Communication Log (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA 21 CFR Part 312 (IND Regulations)
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Operational Guidelines for Ethics Committees
• CDSCO Guidance on Clinical Trials in India

Version: 1.0

Approval Section

Annexures

Annexure-1: Submission Checklist

Annexure-2: Submission Tracker

Annexure-3: Regulatory Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Protocol-Amendments-and-Regulatory-Notifications”
},
“headline”: “SOP for Protocol Amendments and Regulatory Notifications in Clinical Trials”,
“description”: “A regulatory-compliant SOP detailing the step-by-step process for managing clinical trial protocol amendments and regulatory notifications as per ICH GCP, WHO, FDA, EMA, and CDSCO requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Protocol Amendments and Regulatory Notifications in Clinical Trials

Purpose

The purpose of this SOP is to describe the process for preparing, reviewing, submitting, and tracking clinical trial protocol amendments and associated regulatory notifications. This ensures compliance with ICH GCP, GMP, WHO guidelines, and national regulatory authority requirements (FDA, EMA, MHRA, CDSCO, TGA).

Scope

This SOP applies to all clinical research staff, investigators, regulatory affairs personnel, and quality assurance teams involved in protocol amendments and regulatory notifications for ongoing or planned clinical trials. It covers both substantial amendments (those impacting patient safety, trial conduct, or data integrity) and non-substantial amendments.

Responsibilities

• Principal Investigator (PI): Initiates protocol amendment requests and ensures scientific justification.
• Regulatory Affairs Manager: Prepares and submits amendment packages to regulatory authorities and ethics committees.
• Clinical Research Associate (CRA): Communicates changes to site staff and ensures implementation.
• Quality Assurance Officer: Verifies compliance of amendments with regulatory requirements.
• Head of Clinical Research: Approves protocol changes prior to submission.

Accountability

The Regulatory Affairs Head is accountable for ensuring all amendments and notifications are submitted accurately and within the defined timelines. Failure to notify may result in regulatory non-compliance, trial suspension, or penalties.

Procedure

1. Identification of Amendment Requirement
Determine if proposed changes qualify as substantial (e.g., changes to trial endpoints, dosage, inclusion/exclusion criteria) or non-substantial (e.g., administrative corrections).
Document rationale for amendment in an Amendment Request Form.

2. Preparation of Amendment Dossier
Update the Clinical Trial Protocol with tracked changes.
Revise associated documents (e.g., Informed Consent Form, Investigator’s Brochure).
Compile country-specific forms and cover letters.
Ensure updated safety information is included, if applicable.

3. Internal Review and Approval
Submit amendment dossier to QA for compliance review.
Obtain internal approvals from the Head of Clinical Research.
Maintain version control and document history.

4. Submission to Regulatory Authority and Ethics Committee
Submit amendment electronically via eCTD or as required by local authority.
Notify the Ethics Committee/IRB with complete amendment dossier.
Ensure acknowledgment of submission is filed in the Regulatory Communication Log.

5. Notification to Sites and Investigators
Provide site staff with revised protocol and training, if applicable.
Ensure investigators sign acknowledgment of receipt of updated documents.

6. Documentation and Archiving
File all amendment-related documents in the Trial Master File (TMF).
Maintain amendment tracking log for audit readiness.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• eCTD: Electronic Common Technical Document
• TMF: Trial Master File
• EC/IRB: Ethics Committee/Institutional Review Board

Documents

1. Amendment Request Form (Annexure-1)
2. Amendment Tracking Log (Annexure-2)
3. Regulatory Communication Log (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA Guidance on Protocol Amendments
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Good Clinical Practice Guidelines
• CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Annexures

Annexure-1: Amendment Request Form

Annexure-2: Amendment Tracking Log

Annexure-3: Regulatory Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Safety-Updates-Annual-Reports-DSUR-PSUR”
},
“headline”: “SOP for Safety Updates in Clinical Trials (Annual Reports, DSUR, PSUR)”,
“description”: “A detailed SOP aligned with ICH E2F, GCP, and WHO guidelines for preparing and submitting annual safety updates including DSUR and PSUR in clinical trials.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Safety Updates in Clinical Trials (Annual Reports, DSUR, PSUR)

Purpose

The purpose of this SOP is to define the procedures for compiling, reviewing, and submitting safety updates in clinical trials, including Development Safety Update Reports (DSUR), Periodic Safety Update Reports (PSUR), and Annual Safety Reports. These updates ensure ongoing assessment of investigational product safety, regulatory compliance, and protection of trial participants, as per ICH E2F, GCP, and applicable local regulations.

Scope

This SOP applies to all clinical research staff, pharmacovigilance teams, regulatory affairs personnel, and quality assurance officers involved in the preparation, submission, and archiving of annual safety updates. It covers sponsor obligations across multiple regulatory agencies, including FDA, EMA, CDSCO, MHRA, TGA, and WHO.

Responsibilities

• Pharmacovigilance Officer: Collects and analyzes safety data from ongoing trials.
• Regulatory Affairs Manager: Compiles and submits DSUR/PSUR to relevant authorities.
• Principal Investigator: Provides site-specific safety data and narratives.
• Clinical Research Associates (CRAs): Verify accuracy of safety data collected at sites.
• Quality Assurance Officer: Ensures compliance with timelines and content requirements.
• Head of Clinical Research: Final approval before submission.

Accountability

The Head of Pharmacovigilance is accountable for the completeness, accuracy, and timely submission of all safety updates. Non-compliance may result in regulatory action, trial suspension, or safety risks to participants.

Procedure

1. Data Collection and Analysis
Gather adverse event (AE) and serious adverse event (SAE) data from investigators and clinical sites.
Review data from case report forms (CRFs), safety databases, and literature.
Conduct cumulative analysis to identify trends or emerging safety signals.

2. Preparation of DSUR
Follow ICH E2F guidelines for DSUR preparation.
Include global safety data, cumulative summaries, and significant safety issues identified during the reporting year.
Provide benefit-risk evaluation for investigational product.

3. Preparation of PSUR (if applicable)
For marketed products under investigation, prepare PSUR in line with ICH E2C guidelines.
Include post-marketing safety data, spontaneous adverse event reports, and literature findings.

4. Preparation of Annual Safety Reports
Prepare annual safety reports as required by FDA (IND Annual Report) or CDSCO (India).
Provide cumulative safety data, list of SUSARs, and ongoing trial updates.

5. Review and Approval
QA to review draft DSUR/PSUR against regulatory requirements.
Obtain sign-off from Head of Clinical Research and Pharmacovigilance.

6. Submission and Tracking
Submit DSUR/PSUR electronically through regulatory portals (e.g., FDA ESG, EMA CESP).
File proof of submission in Regulatory Communication Log.
Update Safety Update Tracker with submission status and timelines.

7. Archiving
File final DSUR/PSUR in Trial Master File (TMF).
Retain records for at least 5 years post trial completion or as required by local law.

Abbreviations

• SOP: Standard Operating Procedure
• DSUR: Development Safety Update Report
• PSUR: Periodic Safety Update Report
• AE: Adverse Event
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• QA: Quality Assurance
• CRF: Case Report Form
• TMF: Trial Master File

Documents

1. Safety Update Checklist (Annexure-1)
2. Safety Update Tracker (Annexure-2)
3. Regulatory Communication Log (Annexure-3)

References

• ICH E2F – Development Safety Update Report Guidelines
• ICH E2C – Periodic Safety Update Report Guidelines
• ICH E6(R2) Good Clinical Practice
• US FDA IND Annual Reporting Requirements
• EMA and WHO Pharmacovigilance Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: Safety Update Checklist

Annexure-2: Safety Update Tracker

Annexure-3: Regulatory Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Expanded-Access-Compassionate-Use-Submissions”
},
“headline”: “SOP for Expanded Access and Compassionate Use Submissions in Clinical Research”,
“description”: “A regulatory-compliant SOP for managing expanded access and compassionate use submissions, aligned with ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Expanded Access and Compassionate Use Submissions in Clinical Trials

Purpose

The purpose of this SOP is to establish a standardized process for the preparation, submission, and follow-up of Expanded Access and Compassionate Use applications for investigational products. These submissions ensure that patients with serious or life-threatening conditions, who lack therapeutic alternatives, can access investigational drugs outside traditional clinical trials, in compliance with ICH-GCP, WHO, FDA, EMA, CDSCO, and other global regulatory authority requirements.

Scope

This SOP applies to sponsors, investigators, regulatory affairs personnel, and clinical research teams involved in Expanded Access/Compassionate Use submissions. It includes dossier preparation, submission to regulatory authorities and ethics committees, monitoring of patient safety, and documentation requirements.

Responsibilities

• Principal Investigator (PI): Identifies eligible patients and initiates requests for compassionate use.
• Regulatory Affairs Manager: Prepares and submits applications to regulatory agencies and ethics committees.
• Pharmacovigilance Officer: Monitors patient safety and reports adverse events.
• Quality Assurance Officer: Ensures compliance of submissions with applicable regulations.
• Head of Clinical Research: Reviews and approves applications before submission.

Accountability

The Head of Regulatory Affairs is accountable for ensuring compliance with all regulatory requirements for compassionate use submissions. Failure to comply may result in rejection of applications or regulatory sanctions.

Procedure

1. Patient Eligibility Assessment
PI evaluates patient condition to determine eligibility for compassionate use.
Patient must have a serious or life-threatening condition with no satisfactory alternatives.
Obtain informed consent from the patient or legal guardian.

2. Preparation of Submission Dossier
Prepare a comprehensive dossier including patient history, treatment rationale, Investigator’s Brochure, and product safety data.
Include compassionate use protocol, informed consent form, and risk mitigation strategies.
Compile cover letter, application forms, and regulatory checklists.

3. Ethics Committee/IRB Submission
Submit dossier to Ethics Committee (EC) or Institutional Review Board (IRB) for review and approval.
Ensure minutes of approval are documented and archived.

4. Regulatory Authority Submission
Submit application to national regulatory authority (e.g., FDA Expanded Access IND, EMA Compassionate Use Program, CDSCO expanded access submission).
Obtain written authorization prior to product dispensing.

5. Product Supply and Dispensing
Investigational product must be dispensed under controlled conditions.
Maintain product accountability logs and reconcile supply.

6. Safety Monitoring and Reporting
Monitor patients closely for adverse events.
Report SAEs and SUSARs to regulatory authorities within defined timelines.
Document safety follow-up in communication logs.

7. Documentation and Archiving
Maintain all compassionate use documentation in the Trial Master File (TMF).
Retain records for minimum of 5 years post completion.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• EC: Ethics Committee
• IRB: Institutional Review Board
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• TMF: Trial Master File
• IND: Investigational New Drug

Documents

1. Compassionate Use Application Form (Annexure-1)
2. Patient Eligibility and Consent Form (Annexure-2)
3. Compassionate Use Communication Log (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA Expanded Access IND Guidance
• EMA Compassionate Use Program Guidelines
• WHO Good Clinical Practices
• CDSCO Clinical Trial Rules, 2019

Version: 1.0

Approval Section

Annexures

Annexure-1: Compassionate Use Application Form

Annexure-2: Patient Eligibility and Consent Form

Annexure-3: Compassionate Use Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Device-and-IDE-Submissions”
},
“headline”: “SOP for Device and Investigational Device Exemption (IDE) Submissions”,
“description”: “This SOP provides a step-by-step regulatory-compliant process for preparing and submitting device/IDE applications in clinical research, aligned with FDA, EMA, CDSCO, WHO, and ICH GCP guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Device and IDE Submissions in Clinical Trials

Purpose

The purpose of this SOP is to define standardized procedures for preparing, reviewing, submitting, and tracking clinical trial submissions for medical devices, including Investigational Device Exemptions (IDE). It ensures compliance with FDA 21 CFR Part 812, EMA Medical Device Regulation (MDR 2017/745), CDSCO Medical Device Rules (2017), WHO, and ICH GCP guidelines.

Scope

This SOP applies to regulatory affairs, investigators, sponsors, and quality assurance personnel involved in device-related clinical trials. It covers IDE submissions, device clinical trial approvals, ethics committee submissions, and ongoing regulatory reporting for investigational devices.

Responsibilities

• Principal Investigator (PI): Ensures scientific justification for device use and provides clinical data.
• Regulatory Affairs Manager: Compiles and submits IDE/device dossiers to regulatory authorities.
• Clinical Research Associate (CRA): Supports documentation, protocol adherence, and monitoring.
• Quality Assurance Officer: Ensures compliance of device dossier with SOPs and regulations.
• Head of Clinical Research: Approves submissions prior to dispatch.

Accountability

The Regulatory Affairs Head is accountable for ensuring that all IDE/device submissions comply with regulatory requirements and timelines. Non-compliance can lead to clinical hold, rejection, or trial suspension.

Procedure

1. Pre-Submission Preparation
Identify whether device requires IDE submission or local regulatory equivalent.
Collect technical documentation including device description, design dossier, preclinical/bench testing data, and prior clinical experience if available.
Prepare Investigational Plan as per FDA 21 CFR Part 812 or MDR Annex XV.

2. Compilation of Device Submission Dossier
Include Investigator’s Brochure, clinical protocol, informed consent forms, device labeling, and instructions for use.
Provide risk assessment and justification for human use.
Ensure device accountability and traceability procedures are described.

3. Review and Approval
QA reviews dossier against regulatory submission checklists.
Obtain PI and sponsor approval before finalization.

4. Submission to Regulatory Authority
Submit IDE application to FDA (Form FDA 1571/1572 as applicable) or equivalent forms for EMA/CDSCO.
Ensure electronic submission format (e.g., eCopy for FDA, online portal for CDSCO).
Obtain acknowledgment and maintain communication log.

5. Ethics Committee/IRB Approval
Submit device dossier, risk-benefit assessment, and informed consent documents to EC/IRB.
Retain signed EC approval letters in Trial Master File.

6. Post-Approval Compliance
Ensure submission of progress reports, annual IDE reports, and safety updates.
Report Serious Adverse Device Effects (SADEs) within 10 working days to regulatory authorities.
Notify regulatory authorities and EC/IRB of protocol amendments.

7. Documentation and Archiving
Maintain device submission records, acknowledgment receipts, and approval letters in TMF.
Retain documents for minimum of 10 years as per MDR or 5 years post trial completion.

Abbreviations

• SOP: Standard Operating Procedure
• IDE: Investigational Device Exemption
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• EC/IRB: Ethics Committee/Institutional Review Board
• SADE: Serious Adverse Device Effect
• TMF: Trial Master File

Documents

1. Device Submission Checklist (Annexure-1)
2. Device Submission Tracker (Annexure-2)
3. Device Communication Log (Annexure-3)

References

• FDA 21 CFR Part 812 – Investigational Device Exemptions
• EU MDR 2017/745 – Medical Device Regulation
• CDSCO Medical Device Rules (2017)
• ICH E6(R2) – Good Clinical Practice
• WHO Guidance on Clinical Evaluation of Devices

Version: 1.0

Approval Section

Annexures

Annexure-1: Device Submission Checklist

Annexure-2: Device Submission Tracker

Annexure-3: Device Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Initial-EC-IRB-Submission-and-Approval-Tracking”
},
“headline”: “SOP for Initial Ethics Committee and IRB Submission with Approval Tracking”,
“description”: “This SOP provides a regulatory-compliant framework for initial submissions to Ethics Committees/IRBs and for maintaining approval tracking, aligned with ICH GCP, WHO, FDA, EMA, and CDSCO requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Initial EC/IRB Submission and Approval Tracking in Clinical Trials

Purpose

The purpose of this SOP is to provide standardized instructions for preparing, submitting, and tracking initial applications to Ethics Committees (EC) or Institutional Review Boards (IRB) for clinical trials. This ensures compliance with ICH-GCP, WHO, FDA, EMA, and CDSCO requirements while safeguarding the rights, safety, and well-being of trial participants.

Scope

This SOP applies to all clinical trial staff, investigators, regulatory affairs teams, and quality assurance personnel responsible for submitting trial protocols and related documents to EC/IRBs for initial review and approval before trial initiation.

Responsibilities

• Principal Investigator (PI): Prepares the submission package including protocol, informed consent forms, and investigator’s brochure.
• Regulatory Affairs Manager: Coordinates submission and ensures compliance with local and international regulations.
• Clinical Research Associate (CRA): Supports documentation and follows up with EC/IRB on submission status.
• Quality Assurance Officer: Reviews the package for completeness and regulatory compliance.
• Head of Clinical Research: Approves the final submission package prior to dispatch.

Accountability

The Regulatory Affairs Head is accountable for ensuring timely submission and approval tracking of EC/IRB applications. Any delays or errors may result in trial initiation delays or non-compliance findings during inspections.

Procedure

1. Preparation of Submission Package
Collect required documents: Clinical Trial Protocol, Investigator’s Brochure (IB), Informed Consent Form (ICF), Case Report Forms (CRFs), subject recruitment materials, and insurance certificates.
Ensure documents are in line with ICH-GCP and local regulations.
Prepare cover letter summarizing submission contents.

2. Internal Review and Approval
QA reviews submission package for accuracy and completeness.
Obtain approvals from PI and Head of Clinical Research.
Maintain version control for all documents submitted.

3. Submission to EC/IRB
Submit package electronically or in hard copy as per EC/IRB requirements.
Ensure acknowledgment receipt from EC/IRB is obtained and filed.

4. Approval Tracking
Record submission and approval dates in the EC/IRB Approval Tracker.
Follow up periodically with EC/IRB for review status.
File approval letters and conditions in the Trial Master File (TMF).

5. Communication and Implementation
Communicate approval status to sponsor and trial sites.
Implement EC/IRB requirements or conditions before trial initiation.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• IB: Investigator’s Brochure
• ICF: Informed Consent Form
• CRF: Case Report Form
• TMF: Trial Master File

Documents

1. Initial EC/IRB Submission Checklist (Annexure-1)
2. EC/IRB Approval Tracker (Annexure-2)
3. EC/IRB Communication Log (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA 21 CFR Part 56 – Institutional Review Boards
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Operational Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Annexures

Annexure-1: Initial EC/IRB Submission Checklist

Annexure-2: EC/IRB Approval Tracker

Annexure-3: EC/IRB Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Continuing-Review-and-Renewals”
},
“headline”: “SOP for Ethics Committee and IRB Continuing Review and Renewals”,
“description”: “This SOP outlines the regulatory-compliant process for EC/IRB continuing review and renewals to maintain ethical oversight of clinical trials, aligned with ICH GCP, FDA, EMA, CDSCO, and WHO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Continuing Review and Renewals

Purpose

The purpose of this SOP is to describe the process for conducting Ethics Committee (EC) and Institutional Review Board (IRB) continuing reviews and renewals of clinical trials. This ensures ongoing ethical oversight, participant protection, and compliance with ICH-GCP, WHO, FDA, EMA, and CDSCO regulatory requirements.

Scope

This SOP applies to all clinical research staff, investigators, regulatory affairs personnel, and quality assurance officers involved in the preparation, submission, and follow-up of EC/IRB continuing review and renewal applications for clinical trials.

Responsibilities

• Principal Investigator (PI): Prepares progress reports and renewal documents for submission to EC/IRB.
• Regulatory Affairs Manager: Coordinates submissions and ensures compliance with regional requirements.
• Clinical Research Associate (CRA): Collects site-level data and ensures accuracy of reports.
• Quality Assurance Officer: Reviews documents for completeness and compliance with applicable guidelines.
• Head of Clinical Research: Approves submissions before dispatch to EC/IRB.

Accountability

The Regulatory Affairs Head is accountable for ensuring that continuing review and renewal applications are submitted on time, complete, and compliant. Failure to maintain approvals may result in trial suspension or regulatory non-compliance.

Procedure

1. Identification of Renewal Requirement
Determine the renewal due date based on EC/IRB initial approval letter.
Notify PI and study team at least 60 days before renewal deadline.

2. Preparation of Renewal Package
Include protocol progress report, enrollment status, safety summary (AE/SAE reports), deviations, amendments since last approval, and updated Investigator’s Brochure if applicable.
Ensure all documents are updated and signed by responsible personnel.

3. Internal Review
QA reviews renewal package for completeness.
Head of Clinical Research reviews and approves the package.

4. Submission to EC/IRB
Submit renewal package in electronic or paper form as per EC/IRB requirements.
File proof of submission in Regulatory Communication Log.

5. Approval Tracking
Maintain EC/IRB Renewal Tracker with submission and approval dates.
Follow up until approval is received.

6. Post-Approval Implementation
Communicate approval to trial sites and sponsor.
Implement EC/IRB conditions, if any, prior to continuing the trial.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• AE: Adverse Event
• SAE: Serious Adverse Event
• TMF: Trial Master File

Documents

1. EC/IRB Renewal Checklist (Annexure-1)
2. EC/IRB Renewal Tracker (Annexure-2)
3. Regulatory Communication Log (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• US FDA 21 CFR Part 56 – IRB Requirements
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Annexures

Annexure-1: EC/IRB Renewal Checklist

Annexure-2: EC/IRB Renewal Tracker

Annexure-3: Regulatory Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Amendments-and-Notifications”
},
“headline”: “SOP for Ethics Committee and IRB Amendments and Notifications”,
“description”: “This SOP defines standardized procedures for submitting amendments and notifications to Ethics Committees and IRBs, ensuring compliance with ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Amendments and Notifications

Purpose

The purpose of this SOP is to provide guidance on the preparation, submission, and follow-up of amendments and notifications to Ethics Committees (EC) and Institutional Review Boards (IRB). It ensures compliance with international (ICH GCP, WHO) and national (FDA, EMA, CDSCO) requirements for safeguarding trial participants and maintaining ethical oversight.

Scope

This SOP applies to sponsors, investigators, regulatory affairs staff, and quality assurance teams engaged in submitting protocol amendments, administrative changes, and safety-related notifications to EC/IRBs for clinical trials.

Responsibilities

• Principal Investigator (PI): Initiates protocol amendments and notifies EC/IRB of site-level changes.
• Regulatory Affairs Manager: Compiles and submits amendment packages and notifications to EC/IRBs.
• Clinical Research Associate (CRA): Ensures sites implement approved changes and maintains amendment records.
• Quality Assurance Officer: Reviews amendment documents for compliance before submission.
• Head of Clinical Research: Provides final approval before amendment submission.

Accountability

The Regulatory Affairs Head is accountable for ensuring that amendments and notifications are submitted promptly, accurately, and in accordance with regulatory requirements. Non-compliance may result in trial delays, ethical non-conformance, or regulatory findings.

Procedure

1. Identification of Amendment or Notification Requirement
Determine whether change qualifies as substantial (requiring EC/IRB approval) or non-substantial (requiring notification only).
Document reason for amendment or notification in Amendment Request Form.

2. Preparation of Amendment/Notification Package
Update trial documents such as protocol, informed consent forms, or recruitment materials.
Include cover letter, amendment description, justification, and impact analysis.
Compile supporting data (safety reports, investigator’s brochure updates, etc.).

3. Internal Review
QA verifies accuracy, completeness, and compliance with guidelines.
Head of Clinical Research approves final package.

4. Submission to EC/IRB
Submit amendment/notification electronically or in hard copy as per EC/IRB requirements.
Obtain acknowledgment of receipt.
Record submission details in Communication Log.

5. Follow-up and Approval Tracking
Track review and approval timelines in Amendment Tracker.
Respond promptly to EC/IRB queries.
File final approval letters in Trial Master File (TMF).

6. Implementation
Ensure approved changes are implemented at sites.
Provide training for site staff if amendments affect trial conduct.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• TMF: Trial Master File

Documents

1. Amendment Request Form (Annexure-1)
2. Amendment Tracker (Annexure-2)
3. EC/IRB Communication Log (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA 21 CFR Part 56 – IRB Requirements
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Annexures

Annexure-1: Amendment Request Form

Annexure-2: Amendment Tracker

Annexure-3: EC/IRB Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-Quorum-and-Conflict-of-Interest-Handling”
},
“headline”: “SOP for Ethics Committee Quorum and Conflict of Interest Handling”,
“description”: “This SOP describes regulatory-compliant procedures for managing Ethics Committee (EC)/IRB quorum requirements and handling conflicts of interest, in alignment with ICH GCP, WHO, FDA, EMA, and CDSCO standards.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC Quorum and Conflict of Interest Handling

Purpose

The purpose of this SOP is to define the procedures for ensuring that Ethics Committee (EC)/Institutional Review Board (IRB) meetings meet quorum requirements and for managing conflicts of interest (COI) among members. This guarantees unbiased decision-making, participant safety, and compliance with international and local regulatory requirements.

Scope

This SOP applies to all EC/IRB members, secretariat staff, investigators, and sponsors involved in clinical trials reviewed by the EC/IRB. It covers quorum establishment, conflict of interest disclosure, member recusal, documentation, and record-keeping.

Responsibilities

• EC/IRB Chairperson: Ensures quorum is met before review or approval of any protocol and manages COI declarations.
• EC/IRB Secretariat: Maintains attendance logs, COI declarations, and meeting minutes.
• EC/IRB Members: Disclose any conflict of interest prior to participation in protocol review.
• Quality Assurance Officer: Verifies compliance with quorum and COI handling requirements.
• Head of Clinical Research: Oversees adherence to SOP at institutional level.

Accountability

The EC/IRB Chairperson is accountable for ensuring that all meetings adhere to quorum and COI handling requirements. Any deviation may render decisions invalid and result in regulatory non-compliance.

Procedure

1. Quorum Requirements
A quorum is defined as at least 5 voting members, including at least one lay person, one member with medical/scientific expertise, and one member independent of the institution (as per ICH GCP and national guidelines).
Meetings without quorum shall be rescheduled; decisions made without quorum are invalid.

2. Attendance Recording
EC/IRB Secretariat records attendance at each meeting.
Attendance log must include name, designation, role (voting/non-voting), and signature.

3. Conflict of Interest (COI) Disclosure
All members must declare COI before discussion of any protocol where they have financial, academic, or personal interest.
Declarations must be documented in the COI Register (Annexure-2).

4. COI Management
Members with COI shall leave the meeting room during discussion and decision-making.
Their absence and recusal must be recorded in meeting minutes.

5. Documentation and Record Keeping
Secretariat files attendance logs, COI declarations, and minutes in EC/IRB records.
Records are archived in compliance with ICH GCP and local requirements.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• COI: Conflict of Interest
• ICH: International Council for Harmonisation
• GCP: Good Clinical Practice
• QA: Quality Assurance

Documents

1. EC/IRB Attendance Log (Annexure-1)
2. Conflict of Interest Declaration Register (Annexure-2)
3. EC/IRB Meeting Minutes Template (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA 21 CFR Part 56 – IRB Requirements
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Operational Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Annexures

Annexure-1: EC/IRB Attendance Log

Annexure-2: Conflict of Interest Declaration Register

Annexure-3: EC/IRB Meeting Minutes Template

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Communications-Minutes-Decisions-Correspondence”
},
“headline”: “SOP for Ethics Committee and IRB Communications (Minutes, Decisions, Correspondence)”,
“description”: “This SOP outlines procedures for recording and managing Ethics Committee (EC) and Institutional Review Board (IRB) communications, including minutes, decisions, and correspondence, in compliance with ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Communications (Minutes, Decisions, Correspondence)

Purpose

The purpose of this SOP is to establish standardized procedures for documenting and managing all communications with Ethics Committees (EC) and Institutional Review Boards (IRB), including meeting minutes, decisions, approval letters, and correspondence. This ensures transparency, accountability, and compliance with ICH GCP, WHO, FDA, EMA, and CDSCO requirements.

Scope

This SOP applies to all EC/IRB secretariat staff, investigators, sponsors, and regulatory personnel involved in preparing, distributing, and archiving EC/IRB communications for clinical trials. It covers routine communications, formal decisions, minutes of meetings, and correspondence with sponsors or investigators.

Responsibilities

• EC/IRB Chairperson: Ensures minutes accurately reflect deliberations and decisions.
• EC/IRB Secretariat: Prepares minutes, distributes decisions, and maintains correspondence logs.
• Investigators: Respond promptly to EC/IRB queries and implement required actions.
• Quality Assurance Officer: Reviews communication records for completeness and compliance.
• Head of Clinical Research: Oversees adherence to SOP and approves major communications if required.

Accountability

The EC/IRB Secretariat is accountable for ensuring accurate, timely, and secure documentation of all communications. Incomplete or inaccurate records may lead to regulatory non-compliance or invalidation of EC/IRB decisions.

Procedure

1. Preparation of Meeting Minutes
Secretariat drafts meeting minutes within 7 working days of EC/IRB meeting.
Minutes must include quorum details, list of attendees, protocol numbers reviewed, summary of discussions, and decisions taken.
Chairperson reviews and signs final version before distribution.

2. Recording Decisions
All EC/IRB decisions (approval, conditional approval, deferral, or disapproval) must be documented.
Decision letters must be issued to investigators and sponsors within 10 working days.
Copies must be filed in the EC/IRB Communication Log and Trial Master File (TMF).

3. Handling Correspondence
Secretariat maintains a log of all incoming and outgoing communications (letters, emails, faxes).
Each correspondence must include date, sender/receiver, subject, and reference number.
Critical correspondence must be acknowledged in writing.

4. Distribution of Communications
Copies of decisions, approvals, and minutes must be shared with investigators, sponsors, and regulatory authorities (if applicable).
Distribution must be documented in Communication Tracker.

5. Documentation and Archiving
All communications must be archived securely with restricted access.
Records must be retained for a minimum of 5 years after trial completion or longer if required by local regulations.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• TMF: Trial Master File
• QA: Quality Assurance

Documents

1. EC/IRB Meeting Minutes Template (Annexure-1)
2. Decision Letter Template (Annexure-2)
3. Communication Log (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• US FDA 21 CFR Part 56 – IRB Regulations
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, 2019

Version: 1.0

Approval Section

Annexures

Annexure-1: EC/IRB Meeting Minutes Template

Annexure-2: Decision Letter Template

Annexure-3: Communication Log

Revision History

For more SOPs visit: Pharma SOP